Klil-Drori, Adi J <br/><br/>
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.  [electronic resource] 

 -  American journal of hematology  10 2017 
 - E602-E604 p.  digital 
<br/><br/> Publication Type: Comparative Study; Evaluation Study; Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-8652 
<br/><br/><label>Standard No.: </label>10.1002/ajh.24838  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Female<br/>Follow-Up Studies<br/>Fusion Proteins, bcr-abl--blood<br/>Gene Dosage<br/>Humans<br/>Imatinib Mesylate--administration & dosage<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Protein Kinase Inhibitors--administration & dosage<br/>Registries